Latest Ratios: P/E Ratio -7.0x · EV/EBITDA N/A · ROE -63.9%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $159M | $210M | $177M | $92M | $67M | $64M | $101M | $84M | $110M | $104M | $100M |
| Enterprise Value | $163M | $214M | $175M | $86M | $34M | $55M | $85M | $79M | $103M | $68M | $71M |
| P/E Ratio → | -6.97 | — | — | — | — | — | — | 17.22 | — | — | — |
| P/S Ratio | 9.38 | 12.38 | 8.77 | 4.91 | 2.54 | 2.71 | 4.63 | 2.65 | 32.36 | 41.61 | 64.24 |
| P/B Ratio | 3.82 | 4.81 | 5.69 | 2.90 | 6.16 | — | 13.84 | 5.55 | 12.27 | 10.80 | 12.88 |
| P/FCF | — | — | — | — | — | — | — | 11.24 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 10.17 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.62 | 8.66 | 4.61 | 1.29 | 2.30 | 3.91 | 2.49 | 30.39 | 27.16 | 45.72 |
| EV / EBITDA | — | — | — | — | — | — | — | 14.01 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 26.42 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 10.54 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.2% | 19.2% | 13.0% | 19.1% | 49.7% | 36.9% | 34.7% | 62.7% | 38.6% | 36.8% | -38.5% |
| Operating Margin | -149.1% | -149.1% | -95.8% | -83.0% | -28.9% | -47.2% | -40.6% | 14.1% | -116.4% | -548.4% | -1293.6% |
| Net Profit Margin | -140.8% | -140.8% | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% | 15.6% | -31.1% | -887.4% | -1212.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.9% | -63.9% | -96.3% | -31.6% | -619.0% | -1007.5% | -82.0% | 41.1% | -11.4% | -254.7% | -120.9% |
| ROA | -29.9% | -29.9% | -43.2% | -11.5% | -56.2% | -53.3% | -25.7% | 13.1% | -2.7% | -55.4% | -42.8% |
| ROIC | -49.5% | -49.5% | -52.9% | -589.5% | — | — | -844.6% | 55.3% | — | — | — |
| ROCE | -47.0% | -47.0% | -37.8% | -33.1% | -32.6% | -70.5% | -33.3% | 14.8% | -11.5% | -39.6% | -51.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.22 | 0.20 | 0.08 | — | 0.24 | 0.13 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.36 | — | — | — |
| Net Debt / Equity | — | 0.09 | -0.07 | -0.17 | -3.03 | — | -2.15 | -0.35 | -0.75 | -3.75 | -3.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -0.93 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -0.70 | — | — | — |
| Interest Coverage | -35.19 | -35.19 | -52.43 | -18.22 | -120.50 | -75.57 | -42.22 | 14.45 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.33 | 2.33 | 1.97 | 4.59 | 3.80 | 1.39 | 3.17 | 3.43 | 6.68 | 7.64 | 6.25 |
| Quick Ratio | 2.17 | 2.17 | 1.86 | 4.33 | 3.64 | 1.28 | 3.00 | 3.28 | 6.34 | 7.30 | 6.09 |
| Cash Ratio | 2.07 | 2.07 | 1.63 | 3.84 | 2.81 | 1.03 | 2.59 | 2.82 | 4.83 | 6.64 | 5.58 |
| Asset Turnover | — | 0.20 | 0.28 | 0.28 | 0.53 | 1.20 | 0.70 | 0.78 | 0.10 | 0.06 | 0.04 |
| Inventory Turnover | 3.35 | 3.35 | 6.53 | 5.31 | 6.79 | 12.49 | 10.30 | 7.35 | 1.24 | 0.84 | 2.56 |
| Days Sales Outstanding | — | 51.05 | 105.63 | 86.32 | 133.56 | 34.82 | 47.63 | 49.77 | 780.01 | 502.46 | 641.68 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 5.8% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 8.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $10M | $9M | $5M | $4M | $4M | $4M | $4M | $3M | $3M |
Liquidity and dilution risk
Based on current market data, MediWound trades at a price-to-sales multiple of 9.73, which appears disconnected from the company's recent 16.14% year-over-year revenue decline and suggests that investors are pricing in speculative future growth rather than the current reality of a shrinking commercial footprint.
The elevated P/S ratio relative to the company's contracting revenue trajectory implies that the market is heavily discounting the potential success of the EscharEx pipeline. This valuation premium warrants caution, as it assumes a rapid turnaround that is not currently supported by the underlying commercial adoption rates of NexoBrid.
According to historical financial data, MediWound's ROIC has remained deeply negative, reaching -22.8% in 2026Q1, which indicates that the company is failing to generate adequate returns on its invested capital as it struggles to scale its specialized biological manufacturing operations effectively.
The consistent inability to achieve positive returns on capital suggests that the current business model is structurally inefficient. Investors should monitor whether future investments in the chronic wound market can reverse this trend or if the company will continue to destroy value through high fixed-cost overheads.
As reported in recent quarterly filings, the company's cash conversion cycle has been highly volatile, peaking at 112 days in 2024Q3, which highlights significant challenges in managing inventory and receivables relative to the slow pace of commercial product adoption in the U.S. burn care market.
The extended days inventory outstanding, which reached 346 days in 2026Q1, suggests that the company is holding excessive biological inventory that may be subject to shelf-life risks. This inefficiency ties up critical cash resources that are desperately needed to fund ongoing clinical development and operational expenses.
Based on the most recent balance sheet figures, the company's cash and equivalents have dwindled to $4.8 million, a precarious position that leaves little room for error given the persistent operating losses and the absence of a self-sustaining, recurring revenue stream from its core products.
The current liquidity position appears insufficient to support the company's high burn rate for an extended period without external financing. This vulnerability suggests that a dilutive equity raise may be imminent, which would further pressure existing shareholders and complicate the company's long-term capital structure.
Investors frequently misapply the price-to-sales ratio to MediWound, failing to account for the fact that a significant portion of reported revenue is derived from non-recurring government grants rather than sustainable commercial product sales, which obscures the true market demand for the company's enzymatic technology.
Using P/S as a primary valuation tool ignores the lumpy nature of BARDA funding and the underlying weakness in commercial NexoBrid adoption. A more appropriate metric would be an adjusted revenue multiple that excludes government-linked milestone payments to better reflect the company's actual commercial viability.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDWD stock.
MediWound Ltd.'s current P/E ratio is -7.0x. The historical average is 17.2x.
MediWound Ltd.'s return on equity (ROE) is -63.9%. The historical average is -70.9%.
Based on historical data, MediWound Ltd. is trading at a P/E of -7.0x. Compare with industry peers and growth rates for a complete picture.
MediWound Ltd. has 19.2% gross margin and -149.1% operating margin.